Hemostemix Financial Statements From 2010 to 2025
| HMTXF Stock | USD 0.06 0.0004 0.64% |
Check Hemostemix financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Hemostemix's main balance sheet or income statement drivers, such as , as well as many indicators such as . Hemostemix financial statements analysis is a perfect complement when working with Hemostemix Valuation or Volatility modules.
Hemostemix |
Hemostemix OTC Stock Shares Outstanding Analysis
Hemostemix's Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Hemostemix Shares Outstanding | 75.74 M |
Most of Hemostemix's fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Hemostemix is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Based on the latest financial disclosure, Hemostemix has 75.74 M of shares currently outstending. This is 58.05% lower than that of the Biotechnology sector and 29.12% lower than that of the Health Care industry. The shares outstanding for all United States stocks is 86.75% higher than that of the company.
Hemostemix Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Hemostemix's current stock value. Our valuation model uses many indicators to compare Hemostemix value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Hemostemix competition to find correlations between indicators driving Hemostemix's intrinsic value. More Info.Hemostemix is rated # 4 in return on asset category among its peers. It is rated below average in current valuation category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Hemostemix's earnings, one of the primary drivers of an investment's value.About Hemostemix Financial Statements
Hemostemix stakeholders use historical fundamental indicators, such as Hemostemix's revenue or net income, to determine how well the company is positioned to perform in the future. Although Hemostemix investors may analyze each financial statement separately, they are all interrelated. For example, changes in Hemostemix's assets and liabilities are reflected in the revenues and expenses on Hemostemix's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Hemostemix. Please read more on our technical analysis and fundamental analysis pages.
Hemostemix Inc., a biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions. The company is also developing various types of cell products, such as synergetic cell populations and neural cell precursors. Hemostemix is traded on OTC Exchange in the United States.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Other Information on Investing in Hemostemix OTC Stock
Hemostemix financial ratios help investors to determine whether Hemostemix OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Hemostemix with respect to the benefits of owning Hemostemix security.